Which has higher valuation and earnings, IRMD or LIVN?

iRadimed has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 13.89 $22.48M $1.83 49.79 LivaNova $1.39B 2.82 -$242.47M $1.95 36.56

Is IRMD or LIVN more profitable?

iRadimed has a net margin of 27.36% compared to LivaNova's net margin of 7.48%. iRadimed's return on equity of 24.48% beat LivaNova's return on equity. Company Net Margins Return on Equity Return on Assets iRadimed 27.36% 24.48% 21.25% LivaNova 7.48% 16.48% 7.59%

Does the media favor IRMD or LIVN?

In the previous week, iRadimed had 3 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for iRadimed and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.58 beat iRadimed's score of 0.30 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LivaNova 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, IRMD or NVST?

Envista has higher revenue and earnings than iRadimed. iRadimed is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 13.89 $22.48M $1.83 49.79 Envista $2.72B 1.34 $47M $0.41 54.60

Is IRMD or NVST more profitable?

iRadimed has a net margin of 27.36% compared to Envista's net margin of 2.41%. iRadimed's return on equity of 24.48% beat Envista's return on equity. Company Net Margins Return on Equity Return on Assets iRadimed 27.36% 24.48% 21.25% Envista 2.41% 7.11% 3.91%

Does the media refer more to IRTC or IRMD?

In the previous week, iRhythm Technologies and iRhythm Technologies both had 5 articles in the media. iRhythm Technologies' average media sentiment score of 0.79 beat iRadimed's score of 0.30 indicating that iRhythm Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive iRadimed 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, IRMD or MMED?

iRadimed has higher earnings, but lower revenue than MiniMed Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 13.89 $22.48M $1.83 49.79 MiniMed Group $2.99B 1.34 N/A N/A N/A

Does the media favor IRMD or MMED?

In the previous week, MiniMed Group had 4 more articles in the media than iRadimed. MarketBeat recorded 9 mentions for MiniMed Group and 5 mentions for iRadimed. iRadimed's average media sentiment score of 0.30 beat MiniMed Group's score of 0.09 indicating that iRadimed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiniMed Group 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, IRMD or WRBY?

iRadimed has higher earnings, but lower revenue than Warby Parker. iRadimed is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 13.89 $22.48M $1.83 49.79 Warby Parker $871.91M 2.98 $1.64M $0.02 1,214.75

Is IRMD or WRBY more profitable?

iRadimed has a net margin of 27.36% compared to Warby Parker's net margin of 0.15%. iRadimed's return on equity of 24.48% beat Warby Parker's return on equity. Company Net Margins Return on Equity Return on Assets iRadimed 27.36% 24.48% 21.25% Warby Parker 0.15% 2.30% 1.18%

Does the media favor IRMD or WRBY?

In the previous week, iRadimed had 2 more articles in the media than Warby Parker. MarketBeat recorded 5 mentions for iRadimed and 3 mentions for Warby Parker. Warby Parker's average media sentiment score of 0.98 beat iRadimed's score of 0.30 indicating that Warby Parker is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Warby Parker 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

iRadimed (IRMD) Competitors

$91.12 +1.26 (+1.40%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$90.94 -0.18 (-0.19%)

As of 06/3/2026 04:55 PM Eastern

Compare

IRMD vs. LIVN, NVST, IRTC, MMED, and WRBY

Should you buy iRadimed stock or one of its competitors? MarketBeat compares iRadimed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with iRadimed include LivaNova (LIVN), Envista (NVST), iRhythm Technologies (IRTC), MiniMed Group (MMED), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry.

How does iRadimed compare to LivaNova?

iRadimed (NASDAQ:IRMD) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

iRadimed has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	13.89	$22.48M	$1.83	49.79
LivaNova	$1.39B	2.82	-$242.47M	$1.95	36.56

iRadimed has a net margin of 27.36% compared to LivaNova's net margin of 7.48%. iRadimed's return on equity of 24.48% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	27.36%	24.48%	21.25%
LivaNova	7.48%	16.48%	7.59%

In the previous week, iRadimed had 3 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for iRadimed and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.58 beat iRadimed's score of 0.30 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LivaNova	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRadimed has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

iRadimed presently has a consensus price target of $120.00, indicating a potential upside of 31.69%. LivaNova has a consensus price target of $79.38, indicating a potential upside of 11.35%. Given iRadimed's stronger consensus rating and higher possible upside, analysts clearly believe iRadimed is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

92.3% of iRadimed shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 36.8% of iRadimed shares are held by company insiders. Comparatively, 0.4% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

iRadimed beats LivaNova on 12 of the 17 factors compared between the two stocks.

How does iRadimed compare to Envista?

iRadimed (NASDAQ:IRMD) and Envista (NYSE:NVST) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

92.3% of iRadimed shares are owned by institutional investors. 36.8% of iRadimed shares are owned by insiders. Comparatively, 1.0% of Envista shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Envista has higher revenue and earnings than iRadimed. iRadimed is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	13.89	$22.48M	$1.83	49.79
Envista	$2.72B	1.34	$47M	$0.41	54.60

In the previous week, iRadimed had 5 more articles in the media than Envista. MarketBeat recorded 5 mentions for iRadimed and 0 mentions for Envista. Envista's average media sentiment score of 1.00 beat iRadimed's score of 0.30 indicating that Envista is being referred to more favorably in the news media.

Company	Overall Sentiment
iRadimed	Neutral
Envista	Positive

iRadimed has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Envista has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

iRadimed has a net margin of 27.36% compared to Envista's net margin of 2.41%. iRadimed's return on equity of 24.48% beat Envista's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	27.36%	24.48%	21.25%
Envista	2.41%	7.11%	3.91%

iRadimed currently has a consensus price target of $120.00, suggesting a potential upside of 31.69%. Envista has a consensus price target of $28.83, suggesting a potential upside of 28.81%. Given iRadimed's stronger consensus rating and higher possible upside, research analysts clearly believe iRadimed is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

iRadimed beats Envista on 12 of the 17 factors compared between the two stocks.

How does iRadimed compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and iRadimed (NASDAQ:IRMD) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

92.3% of iRadimed shares are owned by institutional investors. 1.0% of iRhythm Technologies shares are owned by insiders. Comparatively, 36.8% of iRadimed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

iRhythm Technologies has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, iRadimed has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

In the previous week, iRhythm Technologies and iRhythm Technologies both had 5 articles in the media. iRhythm Technologies' average media sentiment score of 0.79 beat iRadimed's score of 0.30 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
iRadimed	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

iRhythm Technologies presently has a consensus target price of $189.69, indicating a potential upside of 81.42%. iRadimed has a consensus target price of $120.00, indicating a potential upside of 31.69%. Given iRhythm Technologies' higher possible upside, equities analysts plainly believe iRhythm Technologies is more favorable than iRadimed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

iRadimed has lower revenue, but higher earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	4.60	-$44.55M	-$0.86	N/A
iRadimed	$83.81M	13.89	$22.48M	$1.83	49.79

iRadimed has a net margin of 27.36% compared to iRhythm Technologies' net margin of -3.53%. iRadimed's return on equity of 24.48% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
iRadimed	27.36%	24.48%	21.25%

Summary

iRadimed beats iRhythm Technologies on 10 of the 16 factors compared between the two stocks.

How does iRadimed compare to MiniMed Group?

iRadimed (NASDAQ:IRMD) and MiniMed Group (NASDAQ:MMED) are both medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

In the previous week, MiniMed Group had 4 more articles in the media than iRadimed. MarketBeat recorded 9 mentions for MiniMed Group and 5 mentions for iRadimed. iRadimed's average media sentiment score of 0.30 beat MiniMed Group's score of 0.09 indicating that iRadimed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiniMed Group	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

92.3% of iRadimed shares are held by institutional investors. Comparatively, 19.7% of MiniMed Group shares are held by institutional investors. 36.8% of iRadimed shares are held by company insiders. Comparatively, 2.2% of MiniMed Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

iRadimed has a net margin of 27.36% compared to MiniMed Group's net margin of 0.00%. iRadimed's return on equity of 24.48% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	27.36%	24.48%	21.25%
MiniMed Group	N/A	N/A	N/A

iRadimed has higher earnings, but lower revenue than MiniMed Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	13.89	$22.48M	$1.83	49.79
MiniMed Group	$2.99B	1.34	N/A	N/A	N/A

iRadimed presently has a consensus price target of $120.00, indicating a potential upside of 31.69%. MiniMed Group has a consensus price target of $21.67, indicating a potential upside of 51.94%. Given MiniMed Group's higher probable upside, analysts plainly believe MiniMed Group is more favorable than iRadimed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

iRadimed beats MiniMed Group on 8 of the 12 factors compared between the two stocks.

How does iRadimed compare to Warby Parker?

iRadimed (NASDAQ:IRMD) and Warby Parker (NYSE:WRBY) are both medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

iRadimed has a net margin of 27.36% compared to Warby Parker's net margin of 0.15%. iRadimed's return on equity of 24.48% beat Warby Parker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	27.36%	24.48%	21.25%
Warby Parker	0.15%	2.30%	1.18%

iRadimed currently has a consensus target price of $120.00, indicating a potential upside of 31.69%. Warby Parker has a consensus target price of $29.50, indicating a potential upside of 21.42%. Given iRadimed's stronger consensus rating and higher probable upside, equities analysts plainly believe iRadimed is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Warby Parker	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64

92.3% of iRadimed shares are held by institutional investors. Comparatively, 93.2% of Warby Parker shares are held by institutional investors. 36.8% of iRadimed shares are held by insiders. Comparatively, 16.8% of Warby Parker shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

iRadimed has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Warby Parker has a beta of 1.96, suggesting that its share price is 96% more volatile than the broader market.

iRadimed has higher earnings, but lower revenue than Warby Parker. iRadimed is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	13.89	$22.48M	$1.83	49.79
Warby Parker	$871.91M	2.98	$1.64M	$0.02	1,214.75

In the previous week, iRadimed had 2 more articles in the media than Warby Parker. MarketBeat recorded 5 mentions for iRadimed and 3 mentions for Warby Parker. Warby Parker's average media sentiment score of 0.98 beat iRadimed's score of 0.30 indicating that Warby Parker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Warby Parker	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

iRadimed beats Warby Parker on 11 of the 17 factors compared between the two stocks.

Get iRadimed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRMD vs. The Competition

Export

Metric	iRadimed	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.15B	$7.25B	$6.47B	$12.54B
Dividend Yield	0.89%	1.23%	2.69%	5.22%
P/E Ratio	49.79	45.06	22.39	24.18
Price / Sales	13.89	74.02	520.79	112.26
Price / Cash	48.34	24.22	41.34	57.13
Price / Book	12.25	7.15	9.84	6.72
Net Income	$22.48M	$159.22M	$3.57B	$337.19M
7 Day Performance	-1.16%	-2.00%	-2.46%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	49.92%	0.95%	26.49%	33.10%

iRadimed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRMD iRadimed	2.8538 of 5 stars	$91.12 +1.4%	$120.00 +31.7%	+52.4%	$1.15B	$83.81M	49.79	110	Insider Trade
LIVN LivaNova	3.0307 of 5 stars	$74.94 +1.5%	$79.38 +5.9%	+61.6%	$4.12B	$1.39B	38.43	3,300
NVST Envista	3.4338 of 5 stars	$23.50 +0.3%	$28.83 +22.7%	+19.5%	$3.82B	$2.72B	57.32	12,000
IRTC iRhythm Technologies	4.0204 of 5 stars	$115.04 -1.3%	$191.85 +66.8%	-27.9%	$3.78B	$747.14M	N/A	2,400	Analyst Forecast
MMED MiniMed Group	3.6645 of 5 stars	$11.65 -1.9%	$21.67 +86.0%	N/A	$3.27B	$2.99B	N/A	8,000	News Coverage Earnings Report Options Volume Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRMD) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iRadimed (IRMD) Competitors

IRMD vs. LIVN, NVST, IRTC, MMED, and WRBY

How does iRadimed compare to LivaNova?

Summary

How does iRadimed compare to Envista?

Summary

How does iRadimed compare to iRhythm Technologies?

Summary

How does iRadimed compare to MiniMed Group?

Summary

How does iRadimed compare to Warby Parker?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRMD vs. The Competition

iRadimed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iRadimed (IRMD) Competitors

IRMD vs. LIVN, NVST, IRTC, MMED, and WRBY

How does iRadimed compare to LivaNova?

Which has higher valuation and earnings, IRMD or LIVN?

Is IRMD or LIVN more profitable?

Does the media favor IRMD or LIVN?

Which has more risk and volatility, IRMD or LIVN?

Do analysts recommend IRMD or LIVN?

Do institutionals and insiders hold more shares of IRMD or LIVN?

Summary

How does iRadimed compare to Envista?

Do insiders & institutionals believe in IRMD or NVST?

Which has stronger valuation and earnings, IRMD or NVST?

Does the media favor IRMD or NVST?

Which has more risk and volatility, IRMD or NVST?

Is IRMD or NVST more profitable?

Do analysts rate IRMD or NVST?

Summary

How does iRadimed compare to iRhythm Technologies?

Do insiders and institutionals hold more shares of IRTC or IRMD?

Which has more risk and volatility, IRTC or IRMD?

Does the media refer more to IRTC or IRMD?

Do analysts prefer IRTC or IRMD?

Which has higher valuation & earnings, IRTC or IRMD?

Is IRTC or IRMD more profitable?

Summary

How does iRadimed compare to MiniMed Group?

Does the media favor IRMD or MMED?

Do insiders & institutionals have more ownership in IRMD or MMED?

Is IRMD or MMED more profitable?

Which has higher earnings and valuation, IRMD or MMED?

Do analysts prefer IRMD or MMED?

Summary

How does iRadimed compare to Warby Parker?

Is IRMD or WRBY more profitable?

Do analysts prefer IRMD or WRBY?

Do institutionals and insiders have more ownership in IRMD or WRBY?

Which has more volatility & risk, IRMD or WRBY?

Which has preferable valuation and earnings, IRMD or WRBY?

Does the media favor IRMD or WRBY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRMD vs. The Competition

iRadimed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools